http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
REPEAT/Janssen’s EPREX® (epoetin alfa) Demonstrates Effectiveness as a Treatment for Anaemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
-
New Phase 2 Proof-of-Concept Study Shows Canagliflozin Combination Therapy May Support Chronic Weight Management
-
Janssen’s EPREX® (epoetin alfa) Demonstrates Effectiveness as a Treatment for Anaemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
-
Janssen Offers Positive PFS Data from DARZALEX Combo Phase 3 in Certain Multiple Myeloma
-
Daratumumab Significantly Extended Progression-Free Survival in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma
-
Daratumumab Significantly Extended Progression-Free Survival in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma
-
Janssen Announces Significant Data from CNTO 136 Phase 3 in RA
-
New Janssen Phase 3 Data In Patients With Moderately To Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression And Improved Signs And Symptoms Of Disease
-
Janssen Reports Significant Data from Daratumumab Combo Phase 3 in Multiple Myeloma
-
Daratumumab (DARZALEX®) Combination Therapy Significantly Extended Progression-Free Survival in Previously Treated Patients with Multiple Myeloma
-
Daratumumab (DARZALEX®) Combination Therapy Significantly Extended Progression-Free Survival in Previously Treated Patients with Multiple Myeloma
-
New Data Reveal That Presence of Metastases at Initial Prostate Cancer Diagnosis May Have a Critical Impact on Prognosis for Metastatic Castration-Resistant Patients
-
Janssen's (JNJ) TREVICTA Approved by European Commission as Schizophrenia Treatment
-
European Commission Approves TREVICTA® (paliperidone palmitate a 3-monthly injection), for Maintenance Treatment of Schizophrenia
-
Johnson & Johnson (JNJ) Janssen Receives EC Approval of IMBRUVICA in Newly Diagnosed Chronic Lymphocytic Leukaemia
-
Janssen’s IMBRUVICA®▼(ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukaemia
-
New Phase 3 Study Findings Show STELARA® Maintained Clinical Remission After One Year Of Treatment In Patients With Moderate To Severe Crohn's Disease
-
Janssen' Darzalex Receives EC Approval as Multiple Myeloma Treatment (JNJ)
-
Janssen’s Single-Agent DARZALEX® (daratumumab) Approved by European Commission for Treatment of Multiple Myeloma (MM)
-
BabyCenter Wins the Esteemed Webby "People's Voice Award"
-
Janssen Says ASCO 2016 Attendees Shouldn't Miss Its Presentations; Will Include Oncology, Cardio Compounds
-
Janssen to Present Data from Six Compounds Including Daratumumab and Ibrutinib at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Johnson & Johnson Showcasing its Broad Innovation and Technology Strategies in Consumer and Medical Device Businesses
-
Janssen To Present New Inflammatory Bowel Disease Data At Digestive Disease Week Meeting
-
FDA Expands IMBRUVICA Label to Include New Data from Two Key Phase 3 Trials, Adding Overall Survival and Combination Data
-
Janssen-Cilag Receives Positive CHMP for IMBRUVICA in Previously Untreated CLL
-
Janssen’s IMBRUVICA® (ibrutinib) Receives Positive CHMP Opinion for Expanded Use in Previously Untreated Chronic Lymphocytic Leukaemia Patients
-
Moms Around The World Say Advertisers Miss The Mark On Realistically Portraying Their Lives, According To New BabyCenter® Research
-
Ethicon Announces Completion Of Acquisition Of NeuWave Medical, Inc.
-
Janssen Biotech (JNJ) Enters License Agreement with TESARO (TSRO) for Niraparib
-
Janssen Enters Worldwide Collaboration and License Agreement with TESARO, Inc., for Niraparib in Prostate Cancer
-
Five Year Data from Ethicon-Funded Study Demonstrates Long-Term Benefit of Bariatric Surgery for Control of Diabetes
-
Real-World Study Further Confirms Safety Profile of XARELTO® in Nearly 45,000 People with Non-Valvular Atrial Fibrillation (NVAF), Including Those with Concomitant Diabetes
-
Janssen Receives CHMP Positive Opinion for TREVICTA® (paliperidone palmitate a 3-monthly injection) Recommending Approval in the European Union for the Maintenance Treatment of Schizophrenia
-
Janssen-Cilag Affirms Receipt of Positive CHMP Opinion on DARZALEX in r/r Multiple Myeloma (JNJ)
-
CHMP Issues a Positive Opinion on Janssen’s Single-Agent DARZALEX® (daratumumab)
-
Johnson & Johnson to Webcast Annual Meeting of Shareholders
-
Janssen Disease Interception Unit Advances A Growing Venture Portfolio Focused On Intercepting Diseases Prior To Onset
-
Janssen Presents Positive Data from Phase 3 UNITI-1 of STELARA as Crohn's Disease Treatment (JNJ)
-
STELARA® Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha
-
BabyCenter® Announces Winners Of 2016 Moms' Picks Awards
-
J&J's (JNJ) Ethicon Agrees to Acquire NeuWave Medical
-
Ethicon Announces Agreement To Acquire NeuWave Medical, Inc.
-
BabyCenter® & YouGov Research Reveals That Featuring Diverse Family Types In Advertising Resonates With Today's Parents
-
New Data Released on EVARREST® Fibrin Sealant Patch as a Hemostatic Adjunct in Aortic Reconstruction Surgery
-
U.S. FDA Approves IMBRUVICA® (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia
-
AbbVie (ABBV), J&J (JNJ) Announce FDA Approval of IMBRUVICA as First-Line CLL Treatment
-
BabyCenter® Announces Favorite (And Least Favorite) Celebrity Baby Names Of 2015
-
Johnson & Johnson Partners with Leading Universities to Advance Women's Education in Science, Technology, Engineering, Math, Manufacturing and Design (STEM2D)
-
Johnson & Johnson (JNJ), Verily Life Announce Formation of Verb Surgical
